To include your compound in the COVID-19 Resource Center, submit it here.

Takeda adds CAR T therapies

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is adding chimeric antigen receptor (CAR) T cell therapies to its oncology pipeline by partnering

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE